Semin Thromb Hemost 2013; 39(05): 549-558
DOI: 10.1055/s-0033-1343893
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pregnancy and Venous Thromboembolism

Stefano Barco
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
2   Department of Internal Medicine, Clinica Medica III, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
Mathilde Nijkeuter
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Saskia Middeldorp
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
30 April 2013 (online)

Abstract

Pregnancy and the postpartum period are associated with an increased risk of venous thromboembolism (VTE), which complicates 1 to 2 of 1,000 pregnancies and represents a leading cause of mortality during pregnancy in developed countries. Strong evidence for the management of pregnancy-related VTE is missing, mostly because pregnant women have been excluded from all major trials investigating different diagnostic tools and treatment regimens. Nevertheless, proper evaluation of the involved risk factors is mandatory to reduce the incidence of pregnancy-related VTE and improve outcomes. Low-molecular-weight heparins are considered as a first-line option in the management of pregnancy-related VTE. With regard to future research, there is a need for methodologically strong studies in pregnant women, especially with respect to risk stratification, optimal heparin doses, usefulness of anti-FXa levels and their correlation with clinical outcomes, and correct management of anticoagulation during delivery.

 
  • References

  • 1 James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194 (5) 1311-1315
  • 2 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5 (4) 692-699
  • 3 Chang J, Elam-Evans LD, Berg CJ , et al. Pregnancy-related mortality surveillance—United States, 1991–1999. MMWR Surveill Summ 2003; 52 (2) 1-8
  • 4 Bourjeily G, Paidas M, Khalil H, Rosene-Montella K, Rodger M. Pulmonary embolism in pregnancy. Lancet 2010; 375 (9713) 500-512
  • 5 McColl MD, Ramsay JE, Tait RC , et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78 (4) 1183-1188
  • 6 Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton III LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143 (10) 697-706
  • 7 Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG 2001; 108 (1) 56-60
  • 8 Gherman RB, Goodwin TM, Leung B, Byrne JD, Hethumumi R, Montoro M. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 1999; 94 (5 Pt 1) 730-734
  • 9 Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999; 54 (4) 265-271
  • 10 Virkus RA, Løkkegaard ECL, Bergholt T, Mogensen U, Langhoff-Roos J, Lidegaard Ø. Venous thromboembolism in pregnant and puerperal women in Denmark 1995-2005. A national cohort study. Thromb Haemost 2011; 106 (2) 304-309
  • 11 White RH, Brickner LA, Scannell KA. ICD-9-CM codes poorly identified venous thromboembolism during pregnancy. J Clin Epidemiol 2004; 57 (9) 985-988
  • 12 Sultan AA, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol 2012; 156 (3) 366-373
  • 13 Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 6 (6) 905-912
  • 14 Danilenko-Dixon DR, Heit JA, Silverstein MD , et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 2001; 184 (2) 104-110
  • 15 Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos A-M, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl) e691S-736S
  • 16 Lussana F, Coppens M, Cattaneo M, Middeldorp S. Pregnancy-related venous thromboembolism: risk and the effect of thromboprophylaxis. Thromb Res 2012; 129 (6) 673-680
  • 17 Robertson L, Wu O, Langhorne P , et al; Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study . Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132 (2) 171-196
  • 18 Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63 (2) 319-320
  • 19 Bezemer ID, van der Meer FJM, Eikenboom JCJ, Rosendaal FR, Doggen CJM. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169 (6) 610-615
  • 20 Pabinger I, Grafenhofer H, Kyrle PA , et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002; 100 (3) 1060-1062
  • 21 De Stefano V, Martinelli I, Rossi E , et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol 2006; 135 (3) 386-391
  • 22 Bergrem A, Jacobsen EM, Skjeldestad FE, Jacobsen AF, Skogstad M, Sandset PM. The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis—a population-based case-control study. Thromb Res 2010; 125 (5) e222-e227
  • 23 Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol 1997; 104 (2) 191-197
  • 24 Hodges YK, Richer JK, Horwitz KB, Horwitz LD. Variant estrogen and progesterone receptor messages in human vascular smooth muscle. Circulation 1999; 99 (20) 2688-2693
  • 25 Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004; 114 (5-6) 409-414
  • 26 Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79 (6) 1166-1170
  • 27 Khalafallah AA, Morse M, Al-Barzan A-M , et al. D-dimer levels at different stages of pregnancy in Australian women: a single centre study using two different immunoturbidimetric assays. Thromb Res 2012; 130 (3) e171-e177
  • 28 Bretelle F, Sabatier F, Desprez D , et al. Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 2003; 89 (3) 486-492
  • 29 Chan W-S, Spencer FA, Ginsberg JS. Anatomic distribution of deep vein thrombosis in pregnancy. CMAJ 2010; 182 (7) 657-660
  • 30 Wells PS, Anderson DR, Bormanis J , et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997; 350 (9094) 1795-1798
  • 31 Barrellier MT, Lezin B, Monsallier JM. [Isolated iliac deep venous thrombosis. Study of 48 cases seen in 7 years among 18,297 echo-Doppler evaluations of the lower limbs]. J Mal Vasc 2001; 26 (5) 290-298
  • 32 Leung AN, Bull TM, Jaeschke R , et al; ATS/STR Committee on Pulmonary Embolism in Pregnancy. An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy. Am J Respir Crit Care Med 2011; 184 (10) 1200-1208
  • 33 Shahir K, Goodman LR, Tali A, Thorsen KM, Hellman RS. Pulmonary embolism in pregnancy: CT pulmonary angiography versus perfusion scanning. AJR Am J Roentgenol 2010; 195 (3) W214-20
  • 34 Revel M-P, Cohen S, Sanchez O , et al. Pulmonary embolism during pregnancy: diagnosis with lung scintigraphy or CT angiography?. Radiology 2011; 258 (2) 590-598
  • 35 Middeldorp S. How I treat pregnancy-related venous thromboembolism. Blood 2011; 118 (20) 5394-5400
  • 36 Nijkeuter M, Ginsberg JS, Huisman MV. Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy: a systematic review. J Thromb Haemost 2006; 4 (3) 496-500
  • 37 Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160 (2) 191-196
  • 38 Wesseling J, Van Driel D, Smrkovsky M , et al. Neurological outcome in school-age children after in utero exposure to coumarins. Early Hum Dev 2001; 63 (2) 83-95
  • 39 Wesseling J, Van Driel D, Heymans HS , et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost 2001; 85 (4) 609-613
  • 40 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106 (2) 401-407
  • 41 Lepercq J, Conard J, Borel-Derlon A , et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001; 108 (11) 1134-1140
  • 42 Knight M ; UKOSS . Antenatal pulmonary embolism: risk factors, management and outcomes. BJOG 2008; 115 (4) 453-461
  • 43 Voke J, Keidan J, Pavord S, Spencer NH, Hunt BJ ; British Society for Haematology Obstetric Haematology Group . The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol 2007; 139 (4) 545-558
  • 44 Chunilal SD, Young E, Johnston MA , et al. The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost 2002; 87 (1) 92-97
  • 45 Kovacs MJ, Keeney M. Inter-assay and instrument variability of anti-Xa—results. Thromb Haemost 2000; 84 (1) 138
  • 46 Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181 (5 Pt 1) 1113-1117
  • 47 Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004; 191 (3) 1024-1029
  • 48 Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. BJOG 2003; 110 (2) 139-144
  • 49 Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7 (Suppl. 01) 9-12
  • 50 Linkins L-A, Dans AL, Moores LK , et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 ) Suppl): e495S-530S
  • 51 Gerdsen F, Luxembourg B, Langer F, Bauersachs R, Lindhoff-Last E. A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparin. Blood Coagul Fibrinolysis 2008; 19 (6) 477-481
  • 52 Nagler M, Haslauer M, Wuillemin WA. Fondaparinux - data on efficacy and safety in special situations. Thromb Res 2012; 129 (4) 407-417
  • 53 Ciurzyński M, Jankowski K, Pietrzak B , et al. Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia. Med Sci Monit 2011; 17 (5) CS56 –CS59
  • 54 Knol HM, Schultinge L, Erwich JJHM, Meijer K. Fondaparinux as an alternative anticoagulant therapy during pregnancy. J Thromb Haemost 2010; 8 (8) 1876-1879
  • 55 Dempfle C-EH. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350 (18) 1914-1915
  • 56 GlaxoSmithKline Inc.. Product Monograph—Fondaparinux. Data of text revision: June 7, 2012. Available at: http://www.gsk.ca/english/docs-pdf/product-monographs/Arixtra.pdf . Accessed April 10, 2013
  • 57 Bayer Inc. Product monograph—Rivaroxaban tablet. Date of text revision: July 18, 2012. Available at: http://www.bayer.ca/files/XARELTO-PM-ENG-18JUL2012-154961.pdf . Accessed April 10, 2013
  • 58 Boehringer Ingelheim Canada Ltd. Product monograph—Dabigatran etexilate capsules. Date of text revision: January 27, 2012. Available at: http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/Pradax-pm.pdf . Accessed April 10, 2013
  • 59 Tengborn L, Bergqvist D, Mätzsch T, Bergqvist A, Hedner U. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?. Am J Obstet Gynecol 1989; 160 (1) 90-94
  • 60 Pabinger I, Grafenhofer H, Kaider A , et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005; 3 (5) 949-954
  • 61 Sanson BJ, Lensing AW, Prins MH , et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81 (5) 668-672
  • 62 Brill-Edwards P, Ginsberg JS, Gent M , et al; Recurrence of Clot in This Pregnancy Study Group. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000; 343 (20) 1439-1444
  • 63 Crowther MA, Spitzer K, Julian J , et al. Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study. Thromb Res 2000; 98 (2) 133-138
  • 64 Kominiarek MA, Angelopoulos SM, Shapiro NL, Studee L, Nutescu EA, Hibbard JU. Low-molecular-weight heparin in pregnancy: peripartum bleeding complications. J Perinatol 2007; 27 (6) 329-334
  • 65 Roshani S, Cohn DM, Stehouwer AC , et al. Incidence of postpartum haemorrhage in women receiving therapeutic doses of low-molecular-weight heparin: results of a retrospective cohort study. BMJ Open 2011; 1 (2) e000257
  • 66 Ganguli S, Tham JC, Komlos F, Rabkin DJ. Fracture and migration of a suprarenal inferior vena cava filter in a pregnant patient. J Vasc Interv Radiol 2006; 17 (10) 1707-1711
  • 67 Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 2009; 145 (3) 286-295
  • 68 Musani MH, Matta F, Yaekoub AY, Liang J, Hull RD, Stein PD. Venous compression for prevention of postthrombotic syndrome: a meta-analysis. Am J Med 2010; 123 (8) 735-740
  • 69 Prandoni P, Noventa F, Quintavalla R , et al; Canano Investigators. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. Blood 2012; 119 (6) 1561-1565
  • 70 Wik HS, Jacobsen AF, Sandvik L, Sandset PM. Prevalence and predictors for post-thrombotic syndrome 3 to 16 years after pregnancy-related venous thrombosis: a population-based, cross-sectional, case-control study. J Thromb Haemost 2012; 10 (5) 840-847
  • 71 Verberg MFG, Gillott DJ, Al-Fardan N, Grudzinskas JG. Hyperemesis gravidarum, a literature review. Hum Reprod Update 2005; 11 (5) 527-539
  • 72 Epiney M, Boehlen F, Boulvain M , et al. D-dimer levels during delivery and the postpartum. J Thromb Haemost 2005; 3 (2) 268-271
  • 73 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346 (8983) 1133-1134
  • 74 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88 (10) 3698-3703
  • 75 Tait RC, Walker ID, Perry DJ , et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87 (1) 106-112
  • 76 Miletich J, Sherman L, Broze Jr G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317 (16) 991-996
  • 77 Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113 (3) 636-641
  • 78 Middeldorp S, Henkens CM, Koopman MM , et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128 (1) 15-20
  • 79 Simioni P, Sanson BJ, Prandoni P , et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81 (2) 198-202
  • 80 Middeldorp S, Libourel EJ, Hamulyák K, Van der Meer J, Büller HR. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 2001; 113 (2) 553-555
  • 81 Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001; 86 (3) 800-803
  • 82 Bank I, Libourel EJ, Middeldorp S , et al. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 2004; 164 (17) 1932-1937
  • 83 Friederich PW, Sanson BJ, Simioni P , et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125 (12) 955-960
  • 84 Martinelli I, Battaglioli T, De Stefano V , et al; GIT (Gruppo Italiano Trombofilia). The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A. J Thromb Haemost 2008; 6 (3) 494-498